1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC)
    Meeting Abstract

    Sangro, B.; Harding, J. J.; Johnson, M.; Palmer, D. H.; Edeline, J.; Abou-Alfa, G. K.; Cheng, A. L.; Decaens, T.; El-Khoueiry, A. B.; Finn, R. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors
    Meeting Abstract

    Pauff, J. M.; Papadopoulos, K. P.; Janku, F.; Turk, A. A.; Goyal, L.; Shroff, R. T.; Shimizu, T.; Ikeda, M.; Azad, N. S.; Cleary, J. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Genomic characterization of a comprehensive collection of esophagogastric cancer patient-derived xenografts
    Meeting Abstract

    Moy, R. H.; Mattar, M.; Molena, D.; Strong, V. E.; Jones, D. R.; Coit, D. G.; Tang, L.; Maron, S. B.; Hechtman, J. F.; de Stanchina, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers
    Meeting Abstract

    Pant, S.; Ducreux, M.; Harding, J. J.; Javle, M. M.; Oh, D. Y.; Wasan, H. S.; Fortenberry, A.; Josephson, N. C.; Mwatha, A.; Wang, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • NRG Oncology NRG-GI007 trial-in-progress: Phase I study of OBP-301 (Telomelysin) and definitive chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery
    Meeting Abstract

    Ku, G. Y.; Winter, K. A.; Williams, T. M.; Adusumilli, P. S.; Nishimura, M.; Yock, A.; Ilson, D. H.; Hong, T. S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Wu, A. J. C.; Sihag, S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of early-onset versus average-onset esophagogastric cancer
    Meeting Abstract

    Lumish, M. A.; Sabwa, S.; Maron, S. B.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; Joshi, S. S.; Gu, P.; Strong, V. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas
    Meeting Abstract

    Katz, M. H. G.; Shi, Q.; Meyers, J. P.; Herman, J. M.; Choung, M.; Wolpin, B. M.; Ahmad, S.; de Wilton Marsh, R.; Schwartz, L. H.; Behr, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Global BRAF testing practices in metastatic colorectal cancer
    Meeting Abstract

    Kopetz, S.; Grothey, A.; Ciardiello, F.; Desai, J.; Kim, T. W.; Maughan, T.; Van Cutsem, E.; Wasan, H. S.; Yaeger, R.; Yoshino, T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-ILUSTRO Cohort 3
    Meeting Abstract

    Klempner, S. J.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V. T.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shah, M. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save